Evidence map›Paper›PMID 33997102›Full record

ArticleMolecular therapy. Methods & clinical development2021

Genetically blocking

Peng Gu, Qin Yang, Bangzhu Chen, Ya-Nan Bie, Wen Liu, Yuguang Tian, Hongquan Luo, Tao Xu, Chunjin Liang, Xing Ye and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Peng GuInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Qin YangDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Bangzhu ChenInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Ya-Nan BieInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Wen LiuInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Yuguang TianInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Hongquan LuoInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Tao XuInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Chunjin LiangInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Xing YeInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Yan LiuSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China.
Xiangwu TangSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China.
Weiwang GuInstitute of Comparative Medicine & Laboratory Animal Management Center, Southern Medical University, Guangzhou 510515, China.
Southern Medical University · CNWuyi University · CNChungbuk National University · KRGuangdong Pharmaceutical University · CNNanfang Hospital · CNSongshan Lake Materials Laboratory · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary tyrosinemia type I (HT1) results from the loss of fumarylacetoacetate hydrolase (FAH) activity and can lead to lethal liver injury (LLI). Therapeutic options for HT1 remain limited. The

Indexed as

CRISPR/Cas9HPD ablationlethal liver injuryliver hemeostasismetabolic reprogrammingoxidative stresspigtyrosinemia type I

Identifiers

PMID33997102
PMCPMC8099604
OpenAlexW3155319586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.